Skip to main content

Donepezil News

Cholinesterase Inhibitors Beneficial for Dementia With Lewy Bodies

WEDNESDAY, Aug. 28, 2024 – Cholinesterase inhibitors (ChEIs) are beneficial for patients with dementia with Lewy bodies (DLB), according to a study published online Aug. 23 in Alzheimer's &...

An Alzheimer's Drug May Also Slow Lewy Body Dementia

MONDAY, Aug. 24, 2024 – A type of drug used to treat Alzheimer’s disease appears to slow the progression of Lewy body dementia, the brain disease that afflicted comedian Robin Williams prior to his s...

New Research Points Towards Potential Treatment for Anorexia

THURSDAY, July 11, 2024 – Anorexia nervosa could be caused by lack of a specific brain chemical, reports a research team that has developed a possible cure for the eating disorder. Mouse studies...

Donepezil Not Beneficial for Cognitive Impairment in Breast Cancer Survivors

FRIDAY, May 24, 2024 – A once-daily dose of donepezil does not improve cognitive function among breast cancer survivors exposed to chemotherapy one to five years earlier, according to a study...

FDA Approves Adlarity (donepezil transdermal system) for Treatment of Patients with Alzheimer’s Disease

BOSTON, March 14, 2022 /PRNewswire/ – Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies,...

Eisai Inc. and Pfizer Inc Announce U.S. FDA Approval for New Higher-Dose Aricept (donepezil HCl) 23 mg Tablet for the Treatment of Moderate-to-Severe Alzheimer's Disease

WOODCLIFF LAKE, N.J. & NEW YORK--(BUSINESS WIRE)--Jul 24, 2010 - Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Alzheimer's Disease

Related drug support groups

Aricept

Donepezil patient information at Drugs.com